Web Exclusives

Web Exclusives | August 5, 2020
As many full-service hospitals and health systems remain overwhelmed due to the COVID-19 pandemic, community cancer providers have been able to offer certain services to patients that may not be available at other institutions. How have these providers adapted to meet patients’ changing needs, and how are they keeping their doors open under unprecedented pressure?
Web Exclusives | August 5, 2020
One of the most significant questions for payers in the COVID-19 health ecosystem is, “Will reimbursement parity for telehealth services continue?” Leading representatives of major managed care organizations debate the prospects.
Web Exclusives | August 5, 2020
From shuttered laboratory experiments and interrupted clinical trial enrollments to a “shadow curve” of delayed cancer diagnoses, comprehensive cancer centers and integrated delivery networks (IDNs) across the country continue to grapple with the fallout from COVID-19.
Web Exclusives | July 28, 2020
Shortages, inventory management, and challenges of in-home care were just a few of the topics in AVBCC’s wide-ranging webinar on how COVID-19 is affecting oncology pharmacy.
Web Exclusives | July 28, 2020
As the COVID-19 pandemic stretches into its fifth month in the United States, advocacy groups providing support for patients with cancer are delivering essential support and services, while they worry about the long-term psychosocial impact on these patients and the future of clinical trials.
Web Exclusives | July 20, 2020
As we learn more about the complicated behavior of the COVID-19 virus, we have come to understand that overactivation of the patient’s own immune system can often be the most dangerous factor. In this webcast, top cancer experts discuss the latest studies investigating using anti-cancer therapies as treatments for COVID-19. What are some of the options and where does the research stand today?
Web Exclusives | July 20, 2020
The COVID-19 pandemic has led to the elimination of several restrictions on telehealth and infusion therapy in the home setting. In this webcast, a panel of experts discuss the short- and long-term prospects for in-home infusion for patients with cancer. What are the benefits and drawbacks?
Web Exclusives | June 2, 2020
The COVID-19 pandemic will have far-reaching economic implications in the United States and abroad for the foreseeable future. During this session Murray Aitken, MBA, Director, IQVIA Institute, presented emerging data regarding some of the ways in which the pandemic is affecting the US economy.
Web Exclusives | June 2, 2020
Burt Zweigenhaft, PhD, D.Litt, Founder, Association for Value-Based Cancer Care, moderated a panel session in which 3 experts from the independent actuarial firm, Milliman, discussed recent data showing the ways in which the COVID-19 pandemic may affect the future of healthcare.
Web Exclusives | May 27, 2020
Nurses are on the frontlines of healthcare delivery. In this panel, distinguished nursing professionals discussed topics and issues that have arisen during the pandemic. Led by healthcare educator Lillie D. Shockney, the comprehensive panel covered some of the myriad issues nurse navigators confront now, including rising cancer rates in an aging population, and a decline in numbers of oncology nurses and oncologists.
Web Exclusives | May 12, 2020
In this discussion, moderated by Niesha Griffith, RPh, MS, FASHP, CPO (interim), a panel of oncology pharmacists discuss the impact of the COVID-19 pandemic on their practices, the increase in the use of new technologies as a result of recent events, and how the influx of patients expected in the coming weeks will affect their daily operations.
Web Exclusives | May 12, 2020
Pharmaceutical support and innovation are vital to the effective treatment of patients with cancer. In this discussion, moderated by Burt Zweigenhaft, PhD, D.Litt, a panel of experts discussed the importance of maintaining an adequate supply of medicines for patients, and the need for philanthropic programs to ensure patients will be able to continue their medications, even if they lose their health insurance.
Web Exclusives | April 30, 2020
On April 29, 2020, the FDA accelerated the approval of the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula; GlaxoSmithKline) as the first and only drug approved for first-line maintenance therapy of all patients with advanced ovarian cancer—including epithelial ovarian, fallopian tube, or primary peritoneal cancer—who have had a complete or partial response to first-line platinum-based chemotherapy.
Web Exclusives | April 30, 2020
On April 29, 2020, the FDA accelerated the approval of the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula; GlaxoSmithKline) as the first and only drug approved for first-line maintenance therapy of all patients with advanced ovarian cancer—including epithelial ovarian, fallopian tube, or primary peritoneal cancer—who have had a complete or partial response to first-line platinum-based chemotherapy.
Web Exclusives | April 9, 2020

The Association for Value-Based Cancer Care (AVBCC) webcast was introduced by Dr Zweigenhaft, Founder of AVBCC, who assembled an exceptional group of experts from across the country to discuss the COVID-19 outbreak and its impact on the healthcare industry. After a few quick welcoming remarks to allow more time for the fast-moving presentations, Dr Zweigenhaft introduced Dr Hudis, who briefly presented ASCO’s outlook on the crisis.

Web Exclusives | April 9, 2020

Mr Slotnik opened the session with an inside look at Washington, addressing some of the changes to oncology care policies and operations from the COVID-19 pandemic. He outlined a quick overview of the initiatives from the Centers for Medicare & Medicaid Services (CMS), including new guidelines and the easing of some restrictions on physicians’ options for telemedicine.

Web Exclusives | April 9, 2020

Dr Peskin, Dr Breidbart, and Mr Eyles gave an overview of the changes the novel coronavirus has prompted for managed care payers. They agreed that the unprecedented set of circumstances surrounding the pandemic has led to an opening of the floodgates to questions without immediate answers, leaving providers and payers in unfamiliar territory in a rapidly changing environment with few guideposts.

Web Exclusives | April 9, 2020

Turning from the provision of care to the provision of therapies and essential personal protective equipment (PPE), Mr Pourmahram and Dr Fortner focused on the wholesale supply chain and the challenges of ensuring an uninterrupted flow of crucial materials to areas with the greatest demand.

Web Exclusives | April 9, 2020

Mr Reff and Mr Bailey addressed the modifications that oncology pharmacies are making to keep staff and patients safe during the coronavirus pandemic.

Web Exclusives | April 9, 2020

Less than a month after California issued a stay-at-home order in response to the COVID-19 crisis, oncology practices are seeing declines in their revenue cycles. Mr Gockerman and Mr Shah analyzed the strategies needed to mitigate the downturn.

Web Exclusives | April 1, 2020
This infographic illustrates key findings from the first-of-its-kind study to examine outcomes, evaluate analytics, identify barriers/challenges, analyze performance improvement processes, and identify opportunities for future research.
Web Exclusives | March 20, 2020

Danelle Johnston, MSN, RN, HON-ONN-CG, OCN, and Tricia Strusowski, RN, MS, recapped their recent presentation from the ACCC 46th Annual Meeting & Cancer Center Business Summit, in which they discussed the National Evidence-Based Oncology Navigation Metrics: Multisite Exploratory Study to Demonstrate Value and Sustainability of Navigation Programs. The study was launched in June 2018 as a collaborative effort between the Academy of Oncology Nurse & Patient Navigators (AONN+), Chartis Oncology Solutions, and the American Cancer Society (ACS).

Web Exclusives | February 11, 2020
Pivotal phase 3 data demonstrated treatment with luspatercept resulted in statistically significant increased red blood cell transfusion independence compared with placebo.
Page 1 of 3
Results 1 - 30 of 70

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code